Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Bicycle Therapeutics
Biotech
Bicycle pumps brakes on lead program, deflates headcount by 30%
Shelving drug conjugate zelenectide and laying off staff is meant to extend Bicycle's cash runway into 2030.
Darren Incorvaia
Mar 17, 2026 11:14am
Moderna CMO steps down in leadership mix-up—Chutes & Ladders
Feb 6, 2026 8:30am
Bicycle lays off staff as Genentech rides away from R&D pact
Aug 8, 2025 8:50am
FDA rocked by leadership shake-ups—Chutes & Ladders
Apr 4, 2025 8:30am
BridgeBio, Ipsen, George Medicines and more—Chutes & Ladders
May 3, 2024 8:30am
Bicycle reveals another $1.7B deal, this time with Bayer
May 10, 2023 9:05am
